Cigna to offer $200 Wegovy, Zepbound weight-loss benefit

Cigna will offer a weight-loss drug benefit capping monthly out-of-pocket costs at $200 for Wegovy and Zepbound, a significant discount compared to list prices exceeding $1,000 but in line with cash-pay options. This move comes as FDA policies allowing compounded versions of these drugs are set to expire, potentially shifting market dynamics and increasing demand for name-brand options from Novo Nordisk and Eli Lilly.

Analysis

Cigna's (CI) introduction of a $200 monthly out-of-pocket cap for the weight-loss drugs Wegovy and Zepbound via its pharmacy benefit management (PBM) plans is a strategic move to enhance affordability for these high-demand treatments. This pricing, while significantly below the approximate $1,000 list prices, aligns more closely with direct cash-pay options, such as the reported average of $549 for Zepbound from Eli Lilly (LLY) or $650 for Wegovy from Novo Nordisk (NOVOb.CO) with manufacturer discount cards; importantly, these $200 co-pays will contribute towards patient deductibles. This development is particularly timely as the Food and Drug Administration's policy permitting compounded versions of these GLP-1 agonists is set to conclude on May 22, a shift anticipated to redirect demand towards the patent-holding manufacturers, Novo Nordisk and Eli Lilly. The proven efficacy of Wegovy and Zepbound, which demonstrated a 15% to 20% reduction in body weight in clinical trials, fuels their strong market traction. Cigna's initiative may improve patient adherence and expand access, potentially benefiting its PBM operations. Conversely, companies such as Hims & Hers (HIMS), Noom, and Weight Watchers, which had been supplying compounded versions, face a changed market dynamic, reflected in the slightly negative sentiment score for HIMS, contrasting with the positive sentiment for CI, NOVOb.CO, and LLY.

Key Decisions for Investors

• Investors should monitor Cigna's PBM performance for potential impacts on membership growth and drug cost management, as increased utilization of these therapies could affect overall healthcare expenditures.
• Consider the favorable outlook for Novo Nordisk and Eli Lilly, as Cigna's enhanced coverage and the cessation of FDA-sanctioned compounded alternatives are likely to drive increased sales volumes for Wegovy and Zepbound.
• Evaluate the strategic adjustments and potential revenue headwinds for companies like Hims & Hers, which previously benefited from the sale of compounded weight-loss drugs, following the May 22 FDA policy change.